FDA approved Mirum's Atebrioz (zilurgisertib) on September 25, one day before its target. The sponsor had reported that the study's primary measure—the share of patients developing new heterotopic-ossification lesions—missed statistical significance. FDA's approved use is more specific: reducing the volume of total new bone formation in people with fibrodysplasia ossificans progressiva (FOP) age 12 and older. That is the decision to read, rather than retroactively calling every study endpoint a win. FDA decision · PROGRESS results
The next live date is Egetis' Emcitate on September 28. Its U.S. review asks what a biochemical response, a missed second primary endpoint and supporting rare-disease data can justify in a label. Bristol Myers Squibb's pediatric CAMZYOS expansion follows September 30. Two October oncology applications then bring different questions: a biomarker-defined adjuvant expansion for Tecentriq and the benefit-risk case for a new B7-H3 antibody-drug conjugate.
| Target date | Sponsor / ticker | FDA action under review | Setup class | Main risk | PoA |
|---|---|---|---|---|---|
| Mon Sep 28 | Egetis / EGTX (Stockholm) | Emcitate (tiratricol) / MCT8 deficiency | Priority Review NDA | Biochemical evidence / U.S. claim | — |
| Wed Sep 30 | Bristol Myers Squibb / BMY | CAMZYOS / symptomatic oHCM, ages 12 to under 18 | Priority Review sNDA | Pediatric label / monitoring | 91% |
| Fri Oct 9 | Genentech / Roche / RHHBY | Tecentriq and Tecentriq Hybreza + chemotherapy / resected stage III dMMR or MSI-H colon cancer | Priority Review sBLA | Adjuvant label / biomarker scope | — |
| Sat Oct 10* | Daiichi Sankyo + Merck / MRK | Ifinatamab deruxtecan / previously treated extensive-stage SCLC | Priority Review BLA | Response durability / lung toxicity | — |
The October 10 date is a Saturday target, not a promised public-announcement time. A dash means this issue makes a qualitative assessment rather than publishing a numerical PoA. The 91% CAMZYOS estimate carries forward from the September 21 issue.
Date and filing sources: Egetis, BMS, Genentech, Daiichi Sankyo and Merck.
✓ MIRM / INCY · ATEBRIOZ — APPROVED SEP 25. FDA approved the once-daily ALK2 inhibitor to reduce the volume of total new heterotopic ossification in adults and children 12 and older with FOP. In the 63-patient PROGRESS study, the sponsor reported a primary-endpoint p-value of 0.0986 for the proportion developing new lesions, while a secondary volume measure favored treatment. FDA's public summary identifies the change in total new bone volume as the efficacy basis: an average 3.2 cm³ decrease with Atebrioz versus a 24.6 cm³ increase with placebo at Week 24. The indication describes that measured effect; it does not claim restored mobility or reversal of FOP. FDA decision · Sponsor data
✓ MRK · WINREVAIR — HYPERION DATA ADDED SEP 22. FDA approved an update adding efficacy and safety data from the recently diagnosed PAH population studied in HYPERION. WINREVAIR's adult PAH indication remained in place; the update supplies evidence about treatment earlier after diagnosis, on background therapy. HYPERION reported a 76% relative reduction in clinical-worsening events versus placebo (HR 0.24). The label also added serious-hypersensitivity information. Merck decision and label summary
✓ MRK / EISAI · WELIREG + LENVIMA — APPROVED SEP 24. FDA approved the combination for adults with advanced clear-cell-component renal cell carcinoma after a PD-1 or PD-L1 inhibitor, ahead of its October 4 target. The approved combination has a different place in treatment from WELIREG alone. LITESPARK-011 reported median progression-free survival of 14.6 months versus 10.6 months with cabozantinib; final overall survival was not statistically significant. FDA decision · Merck target-date filing
Biochemical evidence and label scope — EGTX. ReTRIACt found a statistically significant difference in the rate of serum-T3 change after withdrawal from tiratricol. Its second primary endpoint, based on reaching a T3-rescue threshold, did not pass under the prespecified analysis. FDA must assess that study with the rest of the MCT8-deficiency package and decide what U.S. claim the evidence supports. Egetis ReTRIACt results
Pediatric expansion and monitoring — BMY. SCOUT-HCM met its Week 28 left-ventricular-outflow-tract gradient endpoint in 44 adolescents. CAMZYOS already has an adult indication, a boxed warning for heart failure from systolic dysfunction and a REMS. The pediatric decision will be as much about usable dosing and monitoring language as the approval headline. BMS filing and trial summary
Biomarker-defined adjuvant treatment — Genentech. ATOMIC tested Tecentriq plus FOLFOX6 after surgery in stage III mismatch-repair-deficient colon cancer. Genentech reports 36-month disease-free survival of 86% versus 76% with FOLFOX6 alone. FDA is reviewing both the intravenous and subcutaneous formulations; this is one clinical question across two formulations. Genentech filing and ATOMIC data
Single-arm response and safety — MRK / Daiichi Sankyo. The ifinatamab deruxtecan application is based on Phase 2 IDeate-Lung01 responses in previously treated extensive-stage SCLC, with support from IDeate-PanTumor01. The 48.2% confirmed response rate is substantial, but the Lung01 data also include treatment-related interstitial lung disease or pneumonitis in 12.4%, including two fatal cases. The decision and any label will show how FDA balances that record. Filing · IDeate-Lung01 results
The clean read: ReTRIACt randomized 15 patients already stable on tiratricol to continue treatment (n=7) or switch to placebo (n=8). The serum-T3 rate primary endpoint passed (p=0.034). On observed cases, four placebo patients and no tiratricol patients met the rescue criterion (p=0.070). One non-drug-related tiratricol discontinuation was classified as rescue under the statistical analysis plan, making the second primary endpoint 4 placebo versus 1 tiratricol (p=0.182), which did not pass. The completed NDA also includes Triac Trials I and II, the EMC Cohort and Survival studies, and U.S. Expanded Access data. Triac Trial II did not meet its neurodevelopmental primary endpoints in 22 young boys. An EU approval does not determine the U.S. decision or label. ReTRIACt results · Egetis clinical program · U.S. filing
The clean read: The proposed use is for adults with extensive-stage SCLC whose disease progressed on or after platinum chemotherapy. The BLA is based on IDeate-Lung01, with support from IDeate-PanTumor01. In Lung01, blinded independent review found confirmed responses in 48.2% of 137 patients at the 12 mg/kg dose, with a median response duration of 5.3 months. That efficacy analysis pooled the dose-optimization and single-arm expansion groups; it was not a randomized comparison against another treatment. Filing · Primary analysis
Emcitate's serum-T3 result is a direct biochemical finding. Triac Trial II did not meet its neurodevelopmental primary endpoints. The U.S. decision may accept a defined claim from the total package, request more evidence or set a narrower label than an investor expects. Atebrioz is the fresh reminder to read the verb in FDA's indication: its approval says reduce the volume of new bone formation. That is a meaningful outcome, with a defined boundary. Egetis results · Triac Trial II summary · FDA Atebrioz decision
Questions to ask after an adverse action, not claims about undisclosed FDA findings.
| Name | First question after an adverse action |
|---|---|
| EGTX / Emcitate | Did FDA find the biochemical and supporting clinical record insufficient for the proposed U.S. benefit claim? |
| BMY / CAMZYOS | Did pediatric benefit-risk or the monitoring plan fail to support expansion beyond the adult indication? |
| Genentech / Tecentriq | Was the issue the stage III dMMR/MSI-H adjuvant claim, a formulation detail or another stated concern? |
| MRK / ifinatamab deruxtecan | Did FDA object to response evidence, duration, lung toxicity or a different disclosed part of the application? |
MIRM / INCY · Atebrioz: Approved September 25; its September 26 FOP action date leaves the live board. The label is tied to reduction in new heterotopic-ossification volume. FDA
MRK · WINREVAIR: The September 21 HYPERION review resolved with a September 22 label update adding trial efficacy and safety data. Merck
MRK / Eisai · WELIREG + LENVIMA: FDA approved the advanced ccRCC combination September 24, before the October 4 target. FDA
The live board now starts with an unusual rare-disease evidence decision, moves to a pediatric label with an established monitoring framework, then reaches two different October oncology applications. Atebrioz showed that FDA can approve a specifically framed effect even when a sponsor's primary trial measure missed. Emcitate's outcome must be read on its own evidence and on the exact U.S. label, if one is granted.
First clock: EGTX on September 28. Next cleanest expansion question: BMY on September 30. Highest safety scrutiny: Ifinatamab deruxtecan on October 10.
That is the queue.
Follow the FDA decision board. Forward this issue to someone watching the dates but waiting for the actual label before calling the outcome.
Informational only. Not investment advice. Biotech investing carries the risk of total loss.